Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 2006

View Archived Issues

SOCS highlighted at a recent meeting as future drug design targets

Improvements in metabolic risk factors in HIV lipodystrophy study of EG-005

New Japanese agreement for antipruritic agent TRK-820

Syntaxin and Allergan to develop novel clostridial endopeptidase-based compounds

Roswell Park Cancer Institute receives grant to develop aspergillus vaccine

CUV-1647 studied in phase II trial for erythropoietic protoporphyria

Roche requests reexamination of CHMP negative opinion for Tarceva

Major tumor shrinkage observed in study of AS-1411

Arpida completes enrollment in phase III study of iclaprim in cSSSI

ICX-PRO studied in phase II trial for diabetic foot ulcers

Cardioprotective effects of olive oil components

Clinical data indicate that aspirin and clopidogrel do not interact with TGN-255

Spectrum offers Q2 overview

Abbott reports on novel TRPV1 antagonists with efficacy against inflammatory pain

EUK-189 produces encouraging results for treatment of radiation dermatitis

European orphan drug status for TRO-19622 in ALS

Recent Meiji Dairies and NeuroMed patents disclose novel analgesic agents

Virax files to begin phase I/IIa study of VIR-201 HIV vaccine in S. Africa

Pivotal Acapodene studies recommended to continue

New agents for treating neurological disorders disclosed in recent patent literature

End-of-review meeting for indiplon IR NDA

Ajinomoto patents novel coagulation factor Xa inhibitors

Phase III topline results for alvimopan in opioid-induced bowel dysfunction

The immunosuppressive effects of PARP inhibition enhance cardiac graft survival

Novel PI3Kdelta inhibitors reported in recent Ono patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...